STLN
Starling Oncology Inc.
STLN | NASDAQ
$6.50
-$0.03 (-0.46%)
Nov 2, 2026, 10:37 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
PE Ratio | -19.33 | -26.36 | -29 | -41.43 |
PEG Ratio | -0.06 | 0.40 | 0.51 | n/a |
PS Ratio | 1.02 | 1.39 | 2.11 | 4.14 |
PB Ratio | -23.99 | -36.26 | -37.43 | -46.06 |
P/FCF Ratio | -181.86 | -41.24 | -53.20 | -42.72 |
P/OCF Ratio | 1.82K | -50.85 | -62.62 | -44.76 |
OCF/S Ratio | 7.40 | -1.50 | 2.28 | -9.25 |
Debt / Equity Ratio | -4.19 | -6.44 | -6.60 | -8.44 |
Quick Ratio | 1.15 | 1.17 | 1.35 | 1.39 |
Current Ratio | 1.36 | 1.47 | 1.59 | 1.68 |
Asset Turnover | 0.90 | 0.88 | 0.86 | 0.83 |
Interest Coverage | -2.48 | -3.37 | -3.60 | -4.19 |
Return on Equity | 39.29% | 15.30% | 47.76% | 134.46% |
Return on Assets | -5.49% | -1.48% | -4.56% | -10.09% |
Return on Invested Capital | -5.10% | -6.76% | -6.85% | -7.66% |
Dividend Yield | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a |
Gross Profit Margin | 16.84% | 15.81% | 16.04% | 13.85% |
Net Profit Margin | -6.07% | -1.69% | -5.29% | -12.09% |
Pretax Profit Margin | -6.07% | -1.69% | -5.29% | -12.09% |
Operating Profit Margin | -2.86% | -4.42% | -4.87% | -5.90% |
FCF Margin | 6.84% | -2.21% | 1.53% | -9.69% |
EBITDA Margin | -3.78% | 0.72% | -2.79% | -9.42% |
Add to Watchlist
Select watchlists to add or remove STLN